The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type
Fatty Acid
Hydroxamate
Cyclic Peptide
Benzamide

Segment by Application
Treatment of Malignant Tumors
Chronic Disease Treatment
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E

By Company
4SC
Acetylon Pharmaceuticals
Celleron Therapeutics
Chipscreen Biosciences
Chroma Therapeutics
CrystalGenomics
Curis
MEI Pharma
Mirati Therapeutics
Novartis
Onxeo
Repligen
TetraLogic